Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
21/05/2026 23:06
May 21 (Reuters) - Biogen BIIB.O and Denali Therapeutics DNLI.O said on Thursday they will discontinue development of their Parkinson's drug it failed to meet the main goal in a mid-to-late stage study. (Reporting by Sahil Pandey in Bengaluru; Editing by Shailesh Kuber) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers